Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitnib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And Gastro-intestinal Stroma Tumor (Gist).

Trial Profile

Star-tor - Registry For The Evaluation Of The Safety, Tolerability And Efficacy Of Temsirolimus (Torisel®), Sunitinib (Sutent®), And Axitnib (Inlyta®) For The Treatment Of Subjects With Advanced Renal Cell Carcinoma (Mrcc), Mantle Cell Lymphoma (Mcl), And Gastro-intestinal Stroma Tumor (Gist).

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 12 Sep 2017

At a glance

  • Drugs Axitinib (Primary) ; Sunitinib (Primary) ; Temsirolimus (Primary)
  • Indications Gastrointestinal stromal tumours; Mantle-cell lymphoma; Renal cancer; Renal cell carcinoma
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms STAR-TOR
  • Sponsors Pfizer; Wyeth
  • Most Recent Events

    • 12 Sep 2017 Results from 55 patients recruited from Oct 2009 to Feb 2017 presented at the 42nd European Society for Medical Oncology Congress
    • 23 Feb 2017 Planned End Date changed from 1 Dec 2017 to 1 Dec 2019.
    • 23 Feb 2017 Planned primary completion date changed from 1 Sep 2017 to 1 Sep 2019.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top